Arcadia Biosciences EPS RKDA
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$4.55
- Latest quarter, Q2 FY26
- −$2.09
- Fiscal year 2025
- −$1.71
Arcadia Biosciences' earnings per share was −$4.55 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.09.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.71 | n/a |
| FY2024 | −$5.16 | n/a |
| FY2023 | −$14.24 | n/a |
| FY2022 | −$25.88 | n/a |
| FY2021 | −$26.00 | n/a |
| FY2020 | −$22.00 | n/a |
| FY2019 | −$182.40 | n/a |
| FY2018 | −$243.60 | n/a |
| FY2017 | −$291.60 | n/a |
| FY2016 | −$352.00 | n/a |
| FY2015 | −$3280.00 | n/a |
| FY2014 | −$8576.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.09 | n/a | −$4.55 | |
| Q1 FY26 | −$2.11 | −211% | −$5.72 | |
| Q4 FY25 | −$0.97 | n/a | −$1.71 | |
| Q3 FY25 | $0.62 | n/a | −$3.72 | |
| Q2 FY25 | −$3.26 | −518% | −$5.52 | |
| Q1 FY25 | $1.90 | n/a | −$1.48 | |
| Q4 FY24 | −$2.98 | n/a | −$5.16 | |
| Q3 FY24 | −$1.18 | n/a | −$4.28 | |
| Q2 FY24 | $0.78 | +28% | −$4.99 | |
| Q1 FY24 | −$1.78 | n/a | −$5.16 | |
| Q4 FY23 | −$2.10 | n/a | −$14.24 | |
| Q3 FY23 | −$1.89 | n/a | −$18.45 |
Against its peers
Companies in Oil & Gas Exploration & Production nearest Arcadia Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RKDAArcadia Biosciences | −$4.55 | |
| TPETTrio Petroleum | −$3.27 | |
| BRNBarnwell Industries | −$0.49 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| EONREON Resources | n/m | |
| PROPPrairie Operating | −$2.26 | |
| AGIGAbundia Global Impact | n/m | |
| BATLBattalion Oil | −$5.05 | |
| NRTNorth European Oil Royalty Trust | n/m | |
| BSINBig Sky Industrial | −$0.27 | |
| Peer median | −$0.49 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Arcadia Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.